Curis to Present at Upcoming Healthcare Conferences in April
Curis, Inc. (NASDAQ: CRIS), a biotechnology firm focused on cancer therapeutics, announced participation in two upcoming virtual conferences. The Cantor Fitzgerald Future of Oncology Symposium will be held from April 3 to 5, 2023, with a panel presentation on April 5 at 12:00 PM ET. The 22nd Annual Needham Virtual Healthcare Conference is set for April 17 to 20, 2023, featuring Curis on April 20 at 2:15 PM ET. Curis is recognized for its collaborations in immuno-oncology and precision oncology, with ongoing trials for its candidate emavusertib and commercial partnerships for Erivedge®.
- None.
- None.
LEXINGTON, Mass., April 3, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences:
The Cantor Fitzgerald Future of Oncology Symposium, being held virtually from April 3 – 5, 2023. Presentation details are as follows:
- Format: Panel Presentation
- Date: Wednesday, April 5, 2023
- Time: 12:00 PM ET
- A live webcast and archived replay of the panel discussion will be available to registered attendees of the symposium and can be accessed here or through the symposium website.
The 22nd Annual Needham Virtual Healthcare Conference being held on April 17 - 20, 2023. Presentation details are as follows:
- Format: Company Presentation
- Date: Thursday, April 20, 2023
- Time: 2:15 PM ET
About Curis, Inc.
Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, emavusertib (CA-4948). Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma trial in patients with hematologic malignancies, such as non-Hodgkin's lymphoma and other B cell malignancies, both as a monotherapy and in combination with BTK inhibitor ibrutinib, and the Phase 1/2 TakeAim Leukemia trial in patients with acute myeloid leukemia and myelodysplastic syndrome, for which it has received Orphan Drug Designation from the U.S. Food and Drug Administration. The FDA has placed a partial clinical hold on the TakeAim Leukemia trial during which no new patients will be enrolled in the monotherapy expansion phase (Phase 2a) or the combination phase (Phase 1b) of emavusertib with azacitidine or venetoclax. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1 trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-present-at-upcoming-healthcare-conferences-in-april-301787820.html
SOURCE Curis, Inc.
FAQ
What is the date of Curis's presentation at the Cantor Fitzgerald Future of Oncology Symposium?
When is the 22nd Annual Needham Virtual Healthcare Conference featuring Curis?
What is Curis, Inc.'s focus in biotechnology?
What is emavusertib and its current status?
What collaborations is Curis involved in?
